Skip to main content

Table 3 ELISA IgG geometric mean concentrations and proportions of subjects reaching above putative protective antibody concentration (i.e. ≥1.3 μg/mL) before and after vaccination in treatment groups and controls

From: Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment

  RA without DMARD
(n = 50)
RA with MTX
(n = 10)
pSS without DMARD (n = 15) Controls
(n = 49)
Geometric mean concentrations (μg/mL):
 6B prevaccination (95% CI) 0.6 (0.3–1.0) 1.3 (0.5–2.9) 0.6 (0.2–2.0) 0.8 (0.5–1.3)
 6B postvaccination (95% CI) 3.4 (1.8–6.0) 2.1 (0.8–5.6) 2.3 (0.8–6.5) 3.1 (1.9–5.0)
P of increase < 0.001 0.05 0.05 < 0.001
 23F prevaccination (95% CI) 0.5 (0.3–0.8) 1.0 (0.3–3.5) 0.9 (0.4–1.9) 0.6 (0.4–0.9)
 23F postvaccination (95% CI) 2.5 (1.5–4.1) 1.7 (0.7–3.9) 3.5 (1.1–11.5) 3.3 (2.0–5.5)
P of increase < 0.001 0.39 0.006 < 0.001
Proportions of subjects with IgG concentration ≥ 1.3 μg/mL (%):
 6B prevaccination (95% CI) 38 (24–52) 60 (23–97) 33 (6–60) 37 (23–51)
 6B postvaccination (95% CI) 62 (48–76) 70 (35–100) 47 (18–75) 65 (51–79)
P of increase 0.001 0.32 0.16 < 0.001
 23F prevaccination (95% CI) 26 (13–39) 40 (3–77) 47 (18–75) 29 (15–42)
 23F postvaccination (95% CI) 68 (55–81) 60 (23–97) 73 (48–99) 69 (56–83)
P of increase < 0.001 0.16 0.046 < 0.001